DrugDashboards

Prolensa

Bromfenac Sodium · BROMFENAC SODIUM .7 mg/mL · Solution/ Drops · Ophthalmic · Bausch & Lomb Incorporated

NDC 24208-0602-06 · 1 BOTTLE, DROPPER in 1 CARTON / .6 mL in 1 BOTTLE, DROPPER · NDA · View full market →

The short version

7 companies supply this market — a reasonable cushion if one runs into trouble.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 24208-0602-03) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$111.62per unit
middle half $110.62$114.94 · 449 plans · Apr 1, 2026
Est. net of rebates
$66.97–$83.72
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
8%of plans cover it
tier 3 · prior auth 0% · step therapy 0% · qty limit 0%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.2%chance of a new FDA shortage posting for bromfenac sodium (other) in the next 90 days

OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
NDA203168
TE code
AB
Approval date
Apr 5, 2013
Patents / exclusivity
2 patents, 0 exclusivities
TypeNumber / codeExpires
patent9517220Nov 11, 2033
patent10085958Nov 19, 2032

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Bromfenac Sodium (Solution/ Drops)

LabelerStrengthFirst seenLast seen
Alembic Pharmaceuticals Inc.BROMFENAC SODIUM .805 mg/mLJul 15, 2026Sep 2, 2026
Alembic Pharmaceuticals LimitedBROMFENAC SODIUM .805 mg/mLJul 15, 2026Sep 2, 2026
Apotex Corp.BROMFENAC SODIUM .7 mg/mLJul 15, 2026Sep 2, 2026
Bausch & Lomb Americas Inc.BROMFENAC SODIUM .7 mg/mLJul 15, 2026Sep 2, 2026
Bausch & Lomb IncorporatedBROMFENAC SODIUM .7 mg/mLJul 15, 2026Sep 2, 2026
Dr. Reddy's Laboratories Inc.BROMFENAC SODIUM .7 mg/mLJul 15, 2026Sep 2, 2026
Lupin Pharmaceuticals, Inc.BROMFENAC SODIUM .805 mg/mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Prolensa — NDC 24208-0602-06," retrieved September 3, 2026, https://drugdashboards.com/drug/24208060206.

Free to cite with attribution — see how the data is put together.